Current development of CBP/p300 inhibitors in the last decade.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2020.112861
Abstract: CBP/p300, functioning as histone acetyltransferases and transcriptional co-factors, represents an attractive target for various diseases, including malignant tumor. The development of small-molecule inhibitors targeting the bromodomain and HAT domains of CBP/p300 has aroused broad interests… read more here.
Keywords: p300 inhibitors; cbp; development cbp; cbp p300 ... See more keywords